Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALPMY's Cash to Debt is ranked higher than
100% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ALPMY: No Debt )
ALPMY' s 10-Year Cash to Debt Range
Min: 3.62   Max: No Debt
Current: No Debt

Equity to Asset 0.76
ALPMY's Equity to Asset is ranked higher than
82% of the 822 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ALPMY: 0.76 )
ALPMY' s 10-Year Equity to Asset Range
Min: 0.73   Max: 0.78
Current: 0.76

0.73
0.78
Interest Coverage 70.45
ALPMY's Interest Coverage is ranked higher than
67% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.76 vs. ALPMY: 70.45 )
ALPMY' s 10-Year Interest Coverage Range
Min: 66.96   Max: 9999.99
Current: 70.45

66.96
9999.99
F-Score: 6
Z-Score: 7.35
M-Score: -3.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 13.13
ALPMY's Operating margin (%) is ranked higher than
81% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. ALPMY: 13.13 )
ALPMY' s 10-Year Operating margin (%) Range
Min: 10.25   Max: 28.37
Current: 13.13

10.25
28.37
Net-margin (%) 9.69
ALPMY's Net-margin (%) is ranked higher than
80% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. ALPMY: 9.69 )
ALPMY' s 10-Year Net-margin (%) Range
Min: 7.09   Max: 18.24
Current: 9.69

7.09
18.24
ROE (%) 9.49
ALPMY's ROE (%) is ranked higher than
80% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.98 vs. ALPMY: 9.49 )
ALPMY' s 10-Year ROE (%) Range
Min: 4.6   Max: 16.06
Current: 9.49

4.6
16.06
ROA (%) 7.16
ALPMY's ROA (%) is ranked higher than
84% of the 913 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.21 vs. ALPMY: 7.16 )
ALPMY' s 10-Year ROA (%) Range
Min: 3.71   Max: 12.27
Current: 7.16

3.71
12.27
ROC (Joel Greenblatt) (%) 41.22
ALPMY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.70 vs. ALPMY: 41.22 )
ALPMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 30.35   Max: 91.95
Current: 41.22

30.35
91.95
Revenue Growth (3Y)(%) -0.60
ALPMY's Revenue Growth (3Y)(%) is ranked higher than
62% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ALPMY: -0.60 )
ALPMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 9.2
Current: -0.6

0
9.2
EBITDA Growth (3Y)(%) -5.80
ALPMY's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. ALPMY: -5.80 )
ALPMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 5.5
Current: -5.8

0
5.5
EPS Growth (3Y)(%) 3.40
ALPMY's EPS Growth (3Y)(%) is ranked higher than
73% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. ALPMY: 3.40 )
ALPMY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 55.4
Current: 3.4

0
55.4
» ALPMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.50
ALPMY's P/E(ttm) is ranked higher than
90% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.60 vs. ALPMY: 18.50 )
ALPMY' s 10-Year P/E(ttm) Range
Min: 7.26   Max: 53.2
Current: 18.5

7.26
53.2
P/B 2.90
ALPMY's P/B is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. ALPMY: 2.90 )
ALPMY' s 10-Year P/B Range
Min: 1.12   Max: 3.08
Current: 2.9

1.12
3.08
P/S 1.94
ALPMY's P/S is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. ALPMY: 1.94 )
ALPMY' s 10-Year P/S Range
Min: 0.55   Max: 10.2
Current: 1.94

0.55
10.2
PFCF 36.00
ALPMY's PFCF is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 36.00 )
ALPMY' s 10-Year PFCF Range
Min: 6.02   Max: 56.22
Current: 36

6.02
56.22
EV-to-EBIT 20.40
ALPMY's EV-to-EBIT is ranked higher than
85% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.43 vs. ALPMY: 20.40 )
ALPMY' s 10-Year EV-to-EBIT Range
Min: 0.7   Max: 102.9
Current: 20.4

0.7
102.9
Shiller P/E 27.92
ALPMY's Shiller P/E is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.36 vs. ALPMY: 27.92 )
ALPMY' s 10-Year Shiller P/E Range
Min: 17.54   Max: 29.69
Current: 27.92

17.54
29.69
Current Ratio 2.58
ALPMY's Current Ratio is ranked higher than
72% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. ALPMY: 2.58 )
ALPMY' s 10-Year Current Ratio Range
Min: 2.38   Max: 3.64
Current: 2.58

2.38
3.64
Quick Ratio 2.16
ALPMY's Quick Ratio is ranked higher than
76% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ALPMY: 2.16 )
ALPMY' s 10-Year Quick Ratio Range
Min: 1.99   Max: 3.22
Current: 2.16

1.99
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.83
ALPMY's Dividend Yield is ranked higher than
93% of the 519 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. ALPMY: 0.83 )
ALPMY' s 10-Year Dividend Yield Range
Min: 1.58   Max: 6.2
Current: 0.83

1.58
6.2
Dividend Payout 0.31
ALPMY's Dividend Payout is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 0.31 )
ALPMY' s 10-Year Dividend Payout Range
Min: 0.71   Max: 56.8
Current: 0.31

0.71
56.8
Dividend growth (3y) 44.40
ALPMY's Dividend growth (3y) is ranked higher than
97% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ALPMY: 44.40 )
ALPMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 44.4
Current: 44.4

0
44.4
Yield on cost (5-Year) 2.33
ALPMY's Yield on cost (5-Year) is ranked higher than
98% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. ALPMY: 2.33 )
ALPMY' s 10-Year Yield on cost (5-Year) Range
Min: 4.59   Max: 18.03
Current: 2.33

4.59
18.03
Share Buyback Rate -6.70
ALPMY's Share Buyback Rate is ranked higher than
65% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. ALPMY: -6.70 )
ALPMY' s 10-Year Share Buyback Rate Range
Min: 0   Max: -7.1
Current: -6.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 86.64
ALPMY's Price/Net Cash is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 86.64 )
ALPMY' s 10-Year Price/Net Cash Range
Min: 7.27   Max: 147.89
Current: 86.64

7.27
147.89
Price/Net Current Asset Value 31.12
ALPMY's Price/Net Current Asset Value is ranked higher than
80% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 31.12 )
ALPMY' s 10-Year Price/Net Current Asset Value Range
Min: 3.42   Max: 31.84
Current: 31.12

3.42
31.84
Price/Tangible Book 4.21
ALPMY's Price/Tangible Book is ranked higher than
75% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.32 vs. ALPMY: 4.21 )
ALPMY' s 10-Year Price/Tangible Book Range
Min: 1.46   Max: 4.04
Current: 4.21

1.46
4.04
Price/DCF (Projected) 1.95
ALPMY's Price/DCF (Projected) is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. ALPMY: 1.95 )
ALPMY' s 10-Year Price/DCF (Projected) Range
Min: 0.23   Max: 4.73
Current: 1.95

0.23
4.73
Price/Median PS Value 1.42
ALPMY's Price/Median PS Value is ranked higher than
66% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. ALPMY: 1.42 )
ALPMY' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 6.93
Current: 1.42

0.4
6.93
Price/Peter Lynch Fair Value 0.74
ALPMY's Price/Peter Lynch Fair Value is ranked higher than
98% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 0.74 )
ALPMY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.42   Max: 1.71
Current: 0.74

0.42
1.71
Price/Graham Number 2.47
ALPMY's Price/Graham Number is ranked higher than
83% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.17 vs. ALPMY: 2.47 )
ALPMY' s 10-Year Price/Graham Number Range
Min: 0.85   Max: 2.37
Current: 2.47

0.85
2.37
Earnings Yield (Greenblatt) 4.90
ALPMY's Earnings Yield (Greenblatt) is ranked higher than
84% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALPMY: 4.90 )
ALPMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 145.1
Current: 4.9

1
145.1
Forward Rate of Return (Yacktman) 34.44
ALPMY's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.85 vs. ALPMY: 34.44 )
ALPMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.6   Max: 34.9
Current: 34.44

4.6
34.9

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 31
Mar15
Revenue(Mil)
EPS($) 2.29
EPS without NRI($) 2.29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4503.Japan, YPH.Germany,
Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The Company's products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. The Company also offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI.
» More Articles for ALPMY

Headlines

Articles On GuruFocus.com
A Look at Global Investor Charles De Vaulx's Top 5 Holdings Dec 02 2014 
IVA International Fund Q3 2014 Review Oct 29 2014 
Charles de Vaulx’s IVA Worldwide Fund Q3 2014 Review Oct 29 2014 
First Eagle Global Fund Q3 2014 Commentary Oct 28 2014 
First Eagle Overseas Fund Q3 2014 Commentary Oct 28 2014 
Charles de Vaulx's IVA Worldwide Fund Third Quarter 2014 Review Oct 25 2014 
IVA International Fund Q3 2014 Commentary Oct 25 2014 
“Patience is a necessary virtue for value investors” – A Look into the International Value Inv Jun 06 2014 
Charles De Vaulx Reports His Top Five of the First Quarter Jun 03 2014 
IVA International's Charles De Vaulx Reports His Year End Top Stocks Mar 05 2014 

More From Other Websites
Canon Inc. -- Moody's announces rating actions on Japanese corporates following sovereign downgrade Dec 03 2014
AVEO Gains on Tivozanib Agreement with Ophthotech Nov 13 2014
Medivation Q3 Earnings, Revenues Lag Estimates Nov 07 2014
Dana-Farber Cancer Institute And Astellas Announce Research Collaboration Nov 04 2014
Changing Tomorrow Day 2014 Marks Astellas' Fifth Annual Global Service Initiative Nov 04 2014
Astellas Files for Amendment of Isavuconazole Study Protocol Oct 17 2014
Astellas Announces Research Collaboration With Harvard Medical School Investigator For Treatment Of... Oct 14 2014
Astellas' New Data on Cresemba for Invasive Mucormycosis Oct 09 2014
Medivation-Astellas' Xtandi's Label Expanded by FDA Sep 11 2014
U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with... Sep 10 2014
Astellas' Antifungal Under FDA Review, Response by Mar 2015 Sep 08 2014
Astellas-Basilea's Isavuconazole Accepted for EU Review Aug 21 2014
AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss Aug 13 2014
Medivation Jumps on Q2 Earnings Beat, Outlook Encourages Aug 11 2014
Astellas Up on Pipeline Update, Oncology in Focus (revised) Jul 21 2014
Astellas' Isavuconazole Gets QIDP for Invasive Candidiasis Jul 17 2014
Astellas Up on Pipeline Update, Oncology in Focus Jul 16 2014
Astellas Seeks FDA Nod for Fungal Infection Treatment Jul 10 2014
Making Money Around The World Jun 13 2014
Patients Enrolled in Avanir Study Jun 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK